The influence of salt diet on the response to IL-23p40 or IL-17A blocking agents (ustekinumab and secukinumab/ixekizumab, respectively) in patients with psoriasis, CD or spondyloarthritis is another relevant question to examine. Here, IL17A is linked to psoriasis.